
Yaso Therapeutics, Inc. is a startup, clinical stage pharmaceutical company which holds the worldwide license to a novel polyanionic drug, PPCM. Yaso is developing a variety of drug products containing PPCM for topical delivery to treat and prevent all drug-resistant strains of gonorrhea and herpes simplex, and also, to prevent unplanned pregnancies.